First-line therapy for advanced non-small cell lung cancer (NSCLC) involves immunotherapy with or without platinum-based chemotherapy; however, not all patients are fit enough. In the IPSOS trial, atezolizumab monotherapy demonstrated a clinical benefit in platinum-ineligible patients with advanced NSCLC, redefining first-line immunotherapy, and breaking barriers for unfit population in NSCLC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medj.2023.10.002 | DOI Listing |
Publication Analysis
Top Keywords
ipsos trial
8
redefining first-line
8
first-line immunotherapy
8
trial "game
4
"game changer"
4
changer" redefining
4
immunotherapy platinum-ineligible
4
nsclc
4
platinum-ineligible nsclc
4
nsclc first-line
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!